🧪
hypothesis

SCFA Deficiency Disrupts Microglial Homeostasis and Promotes Neurodegeneration

Hypothesis

SCFA Deficiency Disrupts Microglial Homeostasis and Promotes Neurodegeneration

Reduced SCFA-producing bacteria (Lachnospiraceae, Ruminococcaceae, Faecalibacterium) in PD leads to microglial dysfunction, impaired α-synuclein clearance, and increased pro-inflammatory cytokine production.
🧬 HDAC3/GPR43 (FFAR2)/IL10/TREM2/OCLN🩺 neurodegeneration🎯 Composite 58%💱 $0.55▼16.8%proposed
EvidencePending (0%)📖 0 cit🗣 3 debates 12 support 2 oppose
✓ All Quality Gates Passed
Mechanistic 0.65 (15%) Evidence 0.55 (15%) Novelty 0.50 (12%) Feasibility 0.70 (12%) Impact 0.75 (12%) Druggability 0.72 (10%) Safety 0.60 (8%) Competition 0.65 (6%) Data Avail. 0.58 (5%) Reproducible 0.45 (5%) KG Connect 0.50 (8%) 0.583 composite
🏆 ChallengeResolve: SCFA Deficiency Disrupts Microglial Homeostasis and Promotes Neurodegen$250 →
☰ Compare⚔️ Duel⚛️ Collide
📄 Export LaTeX
arXiv PreprintNeurIPSNature MethodsPLOS ONE
📖 Export BibTeXinteract with this hypothesis
Composite58% · Elo1500(0 matches)

🧪 Overview

Reduced SCFA-producing bacteria (Lachnospiraceae, Ruminococcaceae, Faecalibacterium) in PD leads to microglial dysfunction, impaired α-synuclein clearance, and increased pro-inflammatory cytokine production. Butyrate deficiency reduces tight junction expression. Critical translational barriers: butyrate has poor CNS bioavailability (~5% crosses BBB), fecal SCFA is heavily confounded by diet, and SCFA effects may be secondary to prodromal dietary changes. Optimal strategy: high-dose resistant starch (45g/day) rather than direct butyrate supplementation.

🧬 Mechanism

🧬 Curated Mechanism Pathway

Curated pathway from expert analysis

flowchart TD
    A["HDAC3 Class I<br/>Histone Deacetylase 3"]
    B["NCoR/SMRT Complex<br/>Transcriptional Co-repressor"]
    C["H3K9 Deacetylation<br/>Chromatin Condensation"]
    D["Inflammatory Gene Repression<br/>NFKB Pathway Suppression"]
    E["Microglial Activation<br/>Pro-inflammatory Response"]
    F["TREM2 Downregulation<br/>DAM Transition Impaired"]
    G["Phagocytic Capacity<br/>Amyloid Clearance Reduced"]
    H["Synaptic Dysfunction<br/>Memory-Related Gene Expression"]
    I["Cognitive Decline<br/>Neurodegeneration Progression"]
    A --> B
    B --> C
    C --> D
    D --> E
    E --> F
    F --> G
    G --> H
    H --> I
    style A fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
    style I fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a

⚖️ Evidence

⚖️ Evidence Matrix6 supports2 contradicts
Supports
Gut microbiome, short-chain fatty acids, alpha-synuclein, neuroinflammation, and ROS/RNS: relevance to Parkinson's disease.
2024PMID:38377788
Supports
Microbiota-derived short chain fatty acids modulate microglia and promote Aβ plaque clearance.
2021PMID:33845942
Supports
Rifaximin-mediated gut microbiota regulation modulates the function of microglia.
2021PMID:34736493
Supports
Microbial production of short-chain fatty acids attenuates long-term neurologic disease.
2024PMID:41366428
Supports
Inhibition of inflammatory microglia by dietary fiber and short-chain fatty acids.
2022PMID:36797287
Supports
A fiber-deprived diet causes cognitive impairment and hippocampal microglia-mediated neuroinflammation.
2021PMID:34758889
Contradicts
SCFA mechanisms may be species and context-dependent — butyrate, propionate, and acetate have distinct and sometimes opposing effects on different cell types.
2020PMID:31889008
Contradicts
Direct SCFA supplementation trials in human neurodegeneration have shown modest, variable effects; circulating SCFA levels may not reliably predict CNS effects.
📖 Linked Papers (6)Export BibTeX ↗
Molecular Mechanisms Underlying the Regulation of VCAM-1 Expression by the Short-Chain Fatty Acid Butyrate
{'name': 'bioRxiv'} (2025) · PubMed:41473323 ↗
No figures
Poria cocos Polysaccharide Reshapes Gut Microbiota to Regulate Short-Chain Fatty Acids and Alleviate Neuroinflammation-Related Cognitive Impairment in Alzheimer's Disease.
{'name': 'Journal of agricultural and food chemistry'} (2025) · PubMed:40254847 ↗
No figures
Short-chain fatty acids abrogate Japanese encephalitis virus-induced inflammation in microglial cells via miR-200a-3p/ZBTB20/IKβα axis
{'name': 'mBio', 'volume': '15'} (2024) · PubMed:38869276 ↗
No figures
Gut microbiome, short-chain fatty acids, alpha-synuclein, neuroinflammation, and ROS/RNS: Relevance to Parkinson's disease and therapeutic implications.
Redox biology (2024) · PubMed:38377788 ↗
No figures
Rosiglitazone synergizes the neuroprotective effects of valproic acid against quinolinic acid-induced neurotoxicity in rats: targeting PPARγ and HDAC pathways.
Neurotox Res (2014) · PubMed:24566814 ↗
No figures
Valproic acid-mediated neuroprotection in intracerebral hemorrhage via histone deacetylase inhibition and transcriptional activation.
Neurobiol Dis (2007) · PubMed:17398106 ↗
No figures

🏥 Translation

🧬 3D Protein Structure — HDAC3

🧬 PDB 4A69 Click to expand

Experimental structure from RCSB PDB | Powered by Mol*

🧠 GTEx v10 Brain ExpressionJSON

Median TPM across 13 brain regions for HDAC3/GPR43 (FFAR2)/IL10/TREM2/OCLN from GTEx v10.

Cerebellum76.6 Cerebellar Hemisphere75.9 Cortex33.6 Frontal Cortex BA931.7 Nucleus accumbens basal ganglia27.8 Hypothalamus24.1 Anterior cingulate cortex BA2423.6 Caudate basal ganglia21.8 Substantia nigra19.7 Putamen basal ganglia19.3 Spinal cord cervical c-118.1 Hippocampus17.7 Amygdala17.1median TPM (GTEx v10)

💉 Clinical Trials (1)Relevance: 62%

0
Active
0
Completed
0
Total Enrolled
Untitled TrialUnknown
Unknown·

No curated ClinVar variants loaded for this hypothesis.

Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.

🔍 Search ClinVar for HDAC3 →

No DepMap CRISPR Chronos data found for HDAC3.

Run python3 scripts/backfill_hypothesis_depmap.py to populate.

🏆 Tournament

🏆 Arenas / Elo

Elo Rating
1500 ±350
Record
0W / 0L / 0D
0 matches
Full Lineage ➔

📊 Market Indicators

7d Trend
Stable
7d Momentum
▼ 1.3%
Volatility
Low
0.0035
Events (7d)
4
Price History
▼16.8%

💾 Resource Usage

API Calls
3
Total Cost
$0.0000

🔮 Predictions

🔎 Predictions vs Observations2 predictions · 0 with recorded observations
PredictionPredictedObservedStatusConf
IF patients with early-stage Parkinson's disease consume high-dose resistant starch (45g/day) for 12 weeks, THEN fecal SCFA concentrations (particularly butyrate and propionate) will increase by ≥50% ≥50% increase in fecal SCFA; ≥30% reduction in inflammatory cytokines; ≥25% reduction in nigral microglial PET signal— no observation —pending0.65
IF germ-free or antibiotic-depleted α-synuclein transgenic (ASO) mice receive fecal microbiota transplantation from Parkinson's disease patients (vs. healthy controls), THEN colonic HDAC3 activity and≥40% increase in microglial TREM2+ cells; ≥50% increase in IL-10+ microglia; ≥30% reduction in pS129 α-synuclein; ≥20% improvement in motor performance— no observation —pending0.55
🔮 Falsifiable Predictions (2)
pendingconf 65%
IF patients with early-stage Parkinson's disease consume high-dose resistant starch (45g/day) for 12 weeks, THEN fecal SCFA concentrations (particularly butyrate and propionate) will increase by ≥50% AND plasma/CSF inflammatory markers (IL-1β, TNF-α, YKL-40) will decrease by ≥30% compared to placebo
Predicted outcome: ≥50% increase in fecal SCFA; ≥30% reduction in inflammatory cytokines; ≥25% reduction in nigral microglial PET signal
Falsification: Fecal SCFA increase <30% OR inflammatory markers unchanged/increased OR no change/reduction in microglial PET signal. A null result in inflammatory cytokines despite elevated SCFA would indicate that
pendingconf 55%
IF germ-free or antibiotic-depleted α-synuclein transgenic (ASO) mice receive fecal microbiota transplantation from Parkinson's disease patients (vs. healthy controls), THEN colonic HDAC3 activity and GPR43 (FFAR2) expression will normalize by week 4 AND microglial TREM2 expression, IL-10 production
Predicted outcome: ≥40% increase in microglial TREM2+ cells; ≥50% increase in IL-10+ microglia; ≥30% reduction in pS129 α-synuclein; ≥20% improvement in motor performanc
Falsification: No normalization of HDAC3/GPR43 signaling OR microglial TREM2 expression fails to increase OR α-synuclein pathology and motor deficits remain unchanged/worsen. A result showing equivalent pathology de
View on SciDEX ↗